Summary of transaction
Felipe Duran, chief financial officer at iBio, Inc. (NASDAQ: IBIO), reported a purchase of 24,835 shares of common stock on March 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The acquisitions occurred in multiple trades at prices between $2.01 and $2.02 per share, with a weighted average cost of $2.0186. The aggregate consideration for the acquisition was approximately $50,131. After the transactions, Duran holds 35,974 shares of iBio directly.
Market context and analyst perspectives
At the time the filing was reported, iBio’s shares were trading at $2.09. The share price has declined 12.6% over the past week but has gained 162% over the prior six-month period. InvestingPro data cited in company-related reporting indicates analysts have price targets ranging from $4.20 to $7.00 for the stock. A note included in InvestingPro content observed that the company carries more cash than debt on its balance sheet, identified as one of 12 ProTips available to subscribers.
Recent company developments documented alongside the filing
iBio has released preclinical results for IBIO-610, its obesity treatment candidate. In obese non-human primates, the study reported a 6.7% reduction in visceral fat and a 5.2% decrease in total fat mass. Following the disclosure of those preclinical data, Jones Trading reiterated a Buy rating for iBio and set a price target of $7.00, citing the encouraging results for the obesity program.
Separately, the company is expanding its pipeline into pulmonary hypertension associated with heart failure with preserved ejection fraction, with programs targeting myostatin, Activin A, and GDF11. Jones Trading has also initiated coverage highlighting iBio’s extended half-life antibody platform for obesity and metabolic indications, and the firm noted the lead asset is expected to enter clinical trials in 2027.
Financing update
iBio secured approximately $26 million through a private placement financing led by Frazier Life Sciences. The financing involves the sale of more than 11 million shares of common stock, and the transaction was expected to close by January 2026 as disclosed in company-related materials.
Record and disclosure
The insider purchase was disclosed via a Form 4 filed with the SEC. The filing documents the number of shares acquired, the price range per share, the weighted average price, and the insider’s remaining direct holdings following the transactions.
All financial figures, dates, and program details in this report are taken from the filings and company disclosures associated with the transactions and program updates.